HER-2 belongs to the EGFR family, and its overexpression is correlated with the stage of disease and reduced survival in CRC [154,155] as well as in breast cancer and gastric adenocarcinomas [156,157,158]. This evidence concerns the gene ERBB2 and colorectal carcinoma.